The World Health Organization on Friday said the new strain, named omicron, is a “variant of concern” that may pose a higher risk of reinfection than past mutations of the virus.
“We understand the concern of experts and have immediately initiated investigations on variant B.1.1.529,” the companies said.
Pfizer and BioNTech said they expect more data from lab tests in two weeks at the latest.
“These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally,” the companies said.
Pfizer and BioNTech said they can adapt their mRNA vaccine within six weeks and start shipping batches within 100 days if an escape variant is identified.
Johnson & Johnson on Friday said they were already testing their vaccine against omicron.
“We are closely monitoring newly emerging COVID-19 virus strains with variations in the SARS-CoV-2 spike protein and are already testing the effectiveness of our vaccine against the new and rapidly spreading variant first detected in southern Africa,” J&J said.
AstraZeneca said it is also investigating the variant. Its vaccine platform developed with Oxford University enables a quick response to new mutations as they emerge, the company said.
“AstraZeneca is also already conducting research in locations where the variant has been identified, namely in Botswana and Eswatini,” the company said.
Moderna, in a statement Friday, said the combination of mutations in the variant “represents a significant potential risk to accelerate the waning of natural and vaccine-induced immunity.”
“A booster dose of an authorized vaccine represents the only currently available strategy for boosting waning immunity,” the company said.
Moderna said it will test three booster candidates against omicron, including at a higher dosage level. The company will also develop a booster dose specific to the variant.
“From the beginning, we have said that as we seek to defeat the pandemic, it is imperative that we are proactive as the virus evolves,” said Moderna CEO Stephane Bancel in a statement. “The mutations in the Omicron variant are concerning and for several days, we have been moving as fast as possible to execute our strategy to address this variant.”
The variant, which emerged in South Africa, has about 50 mutations, more than 30 of which are on the spike protein that allows the virus to bind to human cells. The spread of the new variant is still in its early stages, and it’s not yet clear how severe an infection would be to a vaccinated person.
Several European and Asian nations have suspended flights from southern Africa in response to the variant. The United Kingdom suspended flights on Thursday from six countries in the region, and the European Commission – the European Union’s executive body – told all 27 member states to halt travel from southern Africa.
White House chief medical advisor Dr. Anthony Fauci on Friday said the U.S. is working with South African scientists to obtain the molecular makeup of the variant so lab tests can be conducted. Those tests would help determine whether or not the variant can evade antibody protection provided by the vaccines.
Fauci said that data would help determine whether or not the U.S. should implement similar travel restrictions. The Biden administration confirmed later on Friday that the U.S. would restrict entry for non-citizens coming from eight southern African nations.
The strength of Covid vaccines against infection has declined over time, although they’re still highly effective at preventing hospitalization and death. A study published in the journal Science this month found that the Pfizer vaccine’s efficacy at preventing infection declined from 86% to 43% from February to October. Moderna’s vaccine dropped from 89% to 58%, and J&J’s vaccine fell from 86% to 13% efficacy against infection in the same study.
The U.S. Centers for Disease Control and Prevention authorized booster shots of Pfizer-BioNTech’s and Moderna’s vaccines for all adults last Friday. The Pfizer booster dose was 95% effective at preventing symptomatic infection in people who had no evidence of prior infection in a clinical trial of 10,000 participants ages 16 and older, according to the company. Moderna is still conducting a clinical trial on the efficacy of its booster dose.
Read More: Pfizer-BioNTech, Moderna, J&J, AstraZeneca investigating omicron